![JoF | Free Full-Text | Lipid Species in the GI Tract are Increased by the Commensal Fungus Candida albicans and Decrease the Virulence of Clostridioides difficile | HTML JoF | Free Full-Text | Lipid Species in the GI Tract are Increased by the Commensal Fungus Candida albicans and Decrease the Virulence of Clostridioides difficile | HTML](https://www.mdpi.com/jof/jof-06-00100/article_deploy/html/images/jof-06-00100-g004.png)
JoF | Free Full-Text | Lipid Species in the GI Tract are Increased by the Commensal Fungus Candida albicans and Decrease the Virulence of Clostridioides difficile | HTML
![Proton pump inhibitor use and risk for recurrent Clostridioides difficile infection: a systematic review and meta-analysis - Clinical Microbiology and Infection Proton pump inhibitor use and risk for recurrent Clostridioides difficile infection: a systematic review and meta-analysis - Clinical Microbiology and Infection](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/b330a187-6bc4-4284-b456-1080eeb9c048/gr1.jpg)
Proton pump inhibitor use and risk for recurrent Clostridioides difficile infection: a systematic review and meta-analysis - Clinical Microbiology and Infection
Epidemiology of Clostridium difficile infection: results of a hospital-based study in Krakow, Poland
![JoF | Free Full-Text | Lipid Species in the GI Tract are Increased by the Commensal Fungus Candida albicans and Decrease the Virulence of Clostridioides difficile | HTML JoF | Free Full-Text | Lipid Species in the GI Tract are Increased by the Commensal Fungus Candida albicans and Decrease the Virulence of Clostridioides difficile | HTML](https://www.mdpi.com/jof/jof-06-00100/article_deploy/html/images/jof-06-00100-g005.png)
JoF | Free Full-Text | Lipid Species in the GI Tract are Increased by the Commensal Fungus Candida albicans and Decrease the Virulence of Clostridioides difficile | HTML
![European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults - Clinical Microbiology and Infection European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults - Clinical Microbiology and Infection](https://www.clinicalmicrobiologyandinfection.com/cms/asset/40ade9b8-1577-446e-aa8d-9636dd47e1b4/gr1.jpg)
European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults - Clinical Microbiology and Infection
![Risk Factors for Recurrent Clostridium difficile Infection: A Systematic Review and Meta-Analysis | Infection Control & Hospital Epidemiology | Cambridge Core Risk Factors for Recurrent Clostridium difficile Infection: A Systematic Review and Meta-Analysis | Infection Control & Hospital Epidemiology | Cambridge Core](https://static.cambridge.org/binary/version/id/urn:cambridge.org:id:binary-alt:20160921234137-24251-mediumThumb-S0899823X14000889_fig2g.jpg?pub-status=live)
Risk Factors for Recurrent Clostridium difficile Infection: A Systematic Review and Meta-Analysis | Infection Control & Hospital Epidemiology | Cambridge Core
![Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial - The Lancet Infectious Diseases Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial - The Lancet Infectious Diseases](https://www.thelancet.com/cms/attachment/9d2398c5-26c4-4c3e-8f65-7e31a1855c05/gr3_lrg.jpg)
Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial - The Lancet Infectious Diseases
![JoF | Free Full-Text | Lipid Species in the GI Tract are Increased by the Commensal Fungus Candida albicans and Decrease the Virulence of Clostridioides difficile | HTML JoF | Free Full-Text | Lipid Species in the GI Tract are Increased by the Commensal Fungus Candida albicans and Decrease the Virulence of Clostridioides difficile | HTML](https://www.mdpi.com/jof/jof-06-00100/article_deploy/html/images/jof-06-00100-g006.png)
JoF | Free Full-Text | Lipid Species in the GI Tract are Increased by the Commensal Fungus Candida albicans and Decrease the Virulence of Clostridioides difficile | HTML
![Lactobacillus rhamnosus L34 and Lactobacillus casei L39 suppress Clostridium difficile-induced IL-8 production by colonic epithelial cells | BMC Microbiology | Full Text Lactobacillus rhamnosus L34 and Lactobacillus casei L39 suppress Clostridium difficile-induced IL-8 production by colonic epithelial cells | BMC Microbiology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2F1471-2180-14-177/MediaObjects/12866_2014_Article_2319_Fig3_HTML.jpg)
Lactobacillus rhamnosus L34 and Lactobacillus casei L39 suppress Clostridium difficile-induced IL-8 production by colonic epithelial cells | BMC Microbiology | Full Text
![Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial - The Lancet Infectious Diseases Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial - The Lancet Infectious Diseases](https://www.thelancet.com/cms/attachment/bee67d79-da32-4f0b-a5c5-e4e572ff6913/gr2_lrg.jpg)
Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial - The Lancet Infectious Diseases
A population-based spatio-temporal analysis of Clostridium difficile infection in Queensland, Australia over a 10-year period
![Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial - The Lancet Infectious Diseases Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial - The Lancet Infectious Diseases](https://www.thelancet.com/cms/attachment/48e264ae-b1e4-44fb-9ece-b23395aca901/gr1_lrg.gif)
Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial - The Lancet Infectious Diseases
![JoF | Free Full-Text | Lipid Species in the GI Tract are Increased by the Commensal Fungus Candida albicans and Decrease the Virulence of Clostridioides difficile | HTML JoF | Free Full-Text | Lipid Species in the GI Tract are Increased by the Commensal Fungus Candida albicans and Decrease the Virulence of Clostridioides difficile | HTML](https://www.mdpi.com/jof/jof-06-00100/article_deploy/html/images/jof-06-00100-g003.png)
JoF | Free Full-Text | Lipid Species in the GI Tract are Increased by the Commensal Fungus Candida albicans and Decrease the Virulence of Clostridioides difficile | HTML
![Proton pump inhibitor use and risk for recurrent Clostridioides difficile infection: a systematic review and meta-analysis - Clinical Microbiology and Infection Proton pump inhibitor use and risk for recurrent Clostridioides difficile infection: a systematic review and meta-analysis - Clinical Microbiology and Infection](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/b33fe995-7d06-4e54-9c4c-f9a3bf788fb7/gr2.jpg)
Proton pump inhibitor use and risk for recurrent Clostridioides difficile infection: a systematic review and meta-analysis - Clinical Microbiology and Infection
Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a ran
![Prognostic factors for severe and recurrent Clostridioides difficile infection: a systematic review - ScienceDirect Prognostic factors for severe and recurrent Clostridioides difficile infection: a systematic review - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1198743X21005528-gr1.jpg)
Prognostic factors for severe and recurrent Clostridioides difficile infection: a systematic review - ScienceDirect
![Incidence and predictive biomarkers of Clostridioides difficile infection in hospitalized patients receiving broad-spectrum antibiotics | Nature Communications Incidence and predictive biomarkers of Clostridioides difficile infection in hospitalized patients receiving broad-spectrum antibiotics | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-021-22269-y/MediaObjects/41467_2021_22269_Fig1_HTML.png)
Incidence and predictive biomarkers of Clostridioides difficile infection in hospitalized patients receiving broad-spectrum antibiotics | Nature Communications
![Effects of proton pump inhibitors and histamine-2 receptor antagonists on response to fidaxomicin or vancomycin in patients with Clostridium difficile-associated diarrhoea | BMJ Open Gastroenterology Effects of proton pump inhibitors and histamine-2 receptor antagonists on response to fidaxomicin or vancomycin in patients with Clostridium difficile-associated diarrhoea | BMJ Open Gastroenterology](https://bmjopengastro.bmj.com/content/bmjgast/2/1/e000028/F1.large.jpg)
Effects of proton pump inhibitors and histamine-2 receptor antagonists on response to fidaxomicin or vancomycin in patients with Clostridium difficile-associated diarrhoea | BMJ Open Gastroenterology
![Incidence and predictive biomarkers of Clostridioides difficile infection in hospitalized patients receiving broad-spectrum antibiotics | Nature Communications Incidence and predictive biomarkers of Clostridioides difficile infection in hospitalized patients receiving broad-spectrum antibiotics | Nature Communications](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41467-021-22269-y/MediaObjects/41467_2021_22269_Fig1_HTML.png)
Incidence and predictive biomarkers of Clostridioides difficile infection in hospitalized patients receiving broad-spectrum antibiotics | Nature Communications
![JoF | Free Full-Text | Lipid Species in the GI Tract are Increased by the Commensal Fungus Candida albicans and Decrease the Virulence of Clostridioides difficile | HTML JoF | Free Full-Text | Lipid Species in the GI Tract are Increased by the Commensal Fungus Candida albicans and Decrease the Virulence of Clostridioides difficile | HTML](https://www.mdpi.com/jof/jof-06-00100/article_deploy/html/images/jof-06-00100-g005-550.jpg)
JoF | Free Full-Text | Lipid Species in the GI Tract are Increased by the Commensal Fungus Candida albicans and Decrease the Virulence of Clostridioides difficile | HTML
![A population-based spatio-temporal analysis of Clostridium difficile infection in Queensland, Australia over a 10-year period - Journal of Infection A population-based spatio-temporal analysis of Clostridium difficile infection in Queensland, Australia over a 10-year period - Journal of Infection](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/ee062183-08a5-4806-a2eb-51ce84ed218f/gr2_lrg.jpg)
A population-based spatio-temporal analysis of Clostridium difficile infection in Queensland, Australia over a 10-year period - Journal of Infection
![Microbiota-based markers predictive of development of Clostridioides difficile infection | Nature Communications Microbiota-based markers predictive of development of Clostridioides difficile infection | Nature Communications](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41467-021-22302-0/MediaObjects/41467_2021_22302_Fig4_HTML.png)